Hazardous anticancer drugs in health care: Environmental exposure assessment

Annals of the New York Academy of Sciences

Volumn 1076, Issue , 2006, Pages 615-623

  Connor, Thomas H ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Antineoplastic drugs; Exposure assessment; Occupational exposure

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BIOLOGICAL MARKER; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM; THIOTEPA;

AIR SAMPLING; ANALYTIC METHOD; BIOSAFETY; BODY FLUID; CHAIR; CHROMOSOME ABERRATION; CONFERENCE PAPER; DANGEROUS GOODS; DRUG CONTAMINATION; ENVIRONMENTAL EXPOSURE; HAZARD ASSESSMENT; HEALTH CARE PERSONNEL; HUMAN; INGESTION; ISOLATION PROCEDURE; METABOLITE; MICRONUCLEUS; MUTAGEN TESTING; OCCUPATIONAL EXPOSURE; SAMPLING; SISTER CHROMATID EXCHANGE; SKIN; URINALYSIS; WORK ENVIRONMENT; WORKPLACE;

EID: 33845646325     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1371.021     Document Type: Conference Paper

References (54)

1. WORLD HEALTH ORGANIZATION (WHO) http://www.who.int/en/
2. CHABNER, B.A., C.J. ALLEGRA, G.A. CURT & P. CALABRESI. 1996. Antineoplastic agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. J.G. HARDMAN & L.E. LIMBIRD, Eds.: 1233-1287. McGraw-Hill. New York.
3. ERLICHMAN, C. & M. MOORE. 1996. Carcinogenesis: a late complication of cancer chemotherapy. In Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd ed. B.A. CHABNER & D.L. LONGO, Eds.: 45-58. Lippincott-Raven. Philadelphia.
4. AMERICAN SOCIETY OF HOSPITAL PHARMACISTS. 1990. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am. J. Hosp. Pharm. 47: 1033-1049.
5. OSHA TECHNICAL MANUAL, TED 1-0.15A, Section VI, Chapter 2, Jan 20, 1999 http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#2
6. NIOSH ALERT: PREVENTING OCCUPATIONAL EXPOSURES TO ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS IN HEALTH CARE SETTINGS 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute.
7. FALCK, K., P. GRÖHN, M. SORSA, et al. 1979. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1: 1250-1251. For Occupational Safety and Health, DHHS (NIOSH) Publication No 2004-165.
8. BAKER, E.S. & T.H. CONNOR. 1996. Monitoring occupational exposure to cancer chemotherapy drugs. Am. J. Health Syst. Pharm. 53: 2713-2723.
9. SORSA, M. & ANDERSON, D. 1996. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat. Res. 355: 253-261.
10. SESSINK, P.J.M. & R.P. BOS. 1999. Drugs hazardous to healthcare workers: evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 20: 347-359.
11. HARRISON, B.R. 2001. Risks of handling cytotoxic drugs. In The Chemotherapy Source Book, 3rd ed. M.C. Perry, Ed.: 566-582. Lippincott, Williams and Wilkins. Philadelphia.
12. SELEVAN, S.G., M.-L. LINDBOHM, R.W. HORNUNG & K. HEMMINKI. 1985. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N. Engl. J. Med. 313: 1173-1178.
13. STÜCKER, I., J.-F. CALIIARD, R. COLLIN, et al. 1990. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand. J. Work Environ. Health 16: 102-107.
14. HEMMINKI, K., P. KYYRÖNEN & M.-L. LINDBOHM. 1985. Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J. Epidemiol. Comm. Health 39: 141-147.
15. PEELEN, S., N. ROELEVELD, D. HEEDERIK, et al. 1999. Toxic Effects on Reproduction in Hospital Personnel. Reproductie-Toxische Effecten Bij Ziekenhuispersonel. Elsevier. Netherlands.
16. VALANIS, B., W.M. VOLLMER & P. STEELE. 1999. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J. Occup. Environ. Med. 41: 632-638.
17. TURCI, R., C. SOTTANI, G. SPAGNOLI & C. MINOIA. 2003. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agent: a review of analytical methods. J. Chromatog. B. 789: 169-209.
18. SESSINK, P.J.M., R.B. ANZION, P.H.H. VAN DER BROEK & R.P. BOS. 1992a. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm. Week Sci. 14: 16-22.
19. SESSINK, P.J.M., K.A. BOER, A.P. SCHEEFHALS, et al. 1992b. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int. Arch. Occup. Environ. Health 64: 105-112.
20. MCDEVITT, J.J., P.S.J. LEES & M.A. MCDIARMID. 1993. Exposure of hospital pharmacists and nurses to antineoplastic agents. J. Occup. Med. 35: 57-60.
21. PETHRAN, A., K. HAUFF, H. HESSEL & C.-H. GRIMM. 1998. Biological, cytogenetic, and ambient monitoring of exposure to antineoplastic drugs. J. Oncol. Pharm. Pract. 4: 57.
22. MINOIA, C., R. TURCI, C. SOTTANI, et al. 1998. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of healthcare personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun. Mass Spectrom. 12: 1485-1493.
23. RUBINO, F.M., L. FLORIDIA, A.M. PIETROPAOLO, et al. 1999. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: applications in occupational hygiene investigations in hospital environments. Med. Lav. 90: 572-583.
24. CONNOR, T.H., R.W. ANDERSON, P.J. SESSINK, et al. 1999. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am. J. Health Syst. Pharm. 56: 1427-1432.
25. MICOLI, G., R. TURCI, M. ARPELLINI & C. MINOIA. 2001. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 750: 25-32.
26. VANDENBROUCKE, J. & H. ROBAYS. 2001. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J. Oncol. Pharm. Pract. 6: 146-152.
27. CONNOR, T.H., R.W. ANDERSON, P.J. SESSINK & S.M. SPIVEY. 2002. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am. J. Health Syst. Pharm. 59: 68-72.
28. KIFFMEYER, T.K., C. KUBE, S. OPIOLKA, et al. 2002. Vapor pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharm. J. 268: 331-337.
29. SCHMAUS, G., R. SCHIERL & S. FUNCK. 2002. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am. J. Health Syst. Pharm. 59: 956-961.
30. WICK, C., M.H. SLAWSON, J.A. JORGENSON & L.S. TYLER. 2003. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am. J. Health Syst. Pharm. 60: 2314-2320.
31. ZEEDIJK, M., B. GREIJDANUS, F.B. STEENSTRA & D.R.A. UGES. 2005. Monitoring exposure of cytotoxics on the hospital ward: measuring surface contamination of four different cytostatic drugs from one wipe sample. Eur. J. Hosp. Pharm. Sci. 11: 18-22.
32. ROS, J.J.W., K.A. SIMONS, J.M. VERZIJL, et al. 1997. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie 13: 168-171.
33. HEPP, R. & G. GENTSCHEW. 1998. External contamination of commercially available cytotoxic drugs. Krankenhauspharmaxie 19: 22-27.
34. DELPORTE, J.P., P. CHENOIX & P.H. HUBERT. 1999. Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur. Hosp. Pharm. 5: 119-121.
35. NYGREN, O., B. GUSTAVSSON, L. STRÖM & A. FRIBERG. 2002. Cisplatin contamination on the outside of drug vials. Ann. Occup. Hyg. 46: 555-557.
36. FAVIER, B., L. GILLES, C. ARDIET & J.F. LATOUR. 2003. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J. Oncol. Pharm. Pract. 9: 15-20.
37. MASON, H.J., J. MORTON, S.J. GARFITT, et al. 2003. Cytotoxic drug contamination on the outside of vails delivered to a hospital pharmacy. Ann. Occup. Hyg. 47: 681-685.
38. CONNOR, T.H., P.J.M. SESSINK, B.R. HARRISON, et al. 2005. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am. J. Health Syst. Pharm. 62: 475-484.
39. ASTM D666-01 STANDARD PRACTICE FOR FIELD COLLECTION OF ORGANIC COMPOUNDS FROM SURFACE USING WIPE SAMPLING. ASTM International. www.astm.org.
40. OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION. EVALUATION GUIDELINES FOR SURFACE SAMPLING METHODS. http://www.osha.gov/dts/sltc/methods/surfacesampling/ t-006-01-0104-m.html Accessed June 15. 2005.
41. NYGREN, O. & C. LUNDGREN. 1997. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int. Arch. Occup. Environ. Health 70: 209-214.
42. SPEZIA, S., B. BOCCA, G. FORTE, et al. 2005. Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field. Rapid Commun. Mass Spectrom. 19: 1551-1556.
43. KLEINBERG, M.L. & M.J. QUINN. 1981. Airborne drug levels in a laminar-flow hood. Am. J. Hosp. Pharm. 38: 1301-1303.
44. DE WERK NEAL A., R.A. WADDEN & W.L. CHIOU. 1983. Exposure of hospital workers to airborne antineoplastic agents. Am. J. Hosp. Pharm. 40: 597-601.
45. MCDIARMID, M.A., T. EGAN, M. FURIO, et al. 1986. Sampling for airborne fluorouracil in a hospital drug preparation area. Am. J. Hosp. Pharm. 43: 1942-1945.
46. PYY, L., M. SORSA & E. HAKALA. 1988. Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am. Ind. Hyg. Assoc. J. 49: 314-317.
47. STUART, A., A.D. STEPHENS, L. WELCH & P.H. SUGERBAKER. 2002. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Annals Surg. Oncol. 9: 186-191.
48. LARSON, R.R., M.B. KHAZAELI & H.K. DILLON. 2003. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl. Occup. Environ. Hyg. 18: 120-131.
49. AMERICAN CONFERENCE OF GOVERNMENT INDUSTRIAL HYGIENISTS. 2004. Threshold Limit Values for Chemical Substances and Physical Agents Biological Exposure Indices. ACGIH. Cincinnati, OH.
50. SARGENT, E.V., B.D. NAUMANN, D.G. DOLAN, et al. 2002. The importance of human data in the establishment of occupational exposure limits. Hum. Ecol. Risk Assess. 8: 805-822.
51. KROMHOUT, H., F. HOEK, R. UITTERHOEVE, et al. 2000. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann. Occup. Hyg. 44: 551-560.
52. SPIVEY, S. & T.H. CONNOR. 2003. Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp. Pharm. 38: 135-139.
53. CONNOR, T.H., M. SHULTS & M.P. FRASER. 2000. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23° and 37°C using a desiccator technique. Mutat. Res. 470: 85-92.
54. HARRISON, B.R., R.J. GODEFROID & E.A. KAVANAUGH. 1996. Quality-assurance testing of staff pharmacists handling cytotoxic drugs. Am. J. Health Syst. Pharm. 53: 402-407.